In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 3, 1996, Pages 1205-1210

  Widness, John A ^a   Veng Pedersen, Peter ^b   Schmidt, Robert L ^a   Lowe, Lance S ^a   Kisthard, James A ^b   Peters, Charles ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; ERYTHROPOIETIN; RADIOACTIVE IODINE; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; HUMAN; KIDNEY; LIVER; LIVER RESECTION; NEPHRECTOMY; PHYSIOLOGY; SHEEP; ANESTHESIA; ANIMAL EXPERIMENT; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANESTHETICS; ANIMALS; BARBITURATES; ERYTHROPOIETIN; HEPATECTOMY; HUMANS; IODINE RADIOISOTOPES; KIDNEY; LIVER; NEPHRECTOMY; RECOMBINANT PROTEINS; SHEEP;

EID: 0030299929     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. AKAIKE, H.: Automatic control: A new look at the statistical model identification. IEEE Trans. 19: 716-723, 1974.
2. BOZZINI, C. E.: Influence of the erythroid activity of the bone marrow on the plasma disappearance of injected erythropoietin in dogs. Nature (Lond.) 1209: 1140-1141, 1966.
3. BROWN, M. S., JONES, M. A., OHLS, R. K. AND CHRISTENSEN, R. D.: Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J. Pediatr. 122: 655-657, 1993.
4. COHEN, R. A., CLEMONS, G. K. AND EBBE, S.: Correlation between bioassay and radioimmunoassay for erythropoietin in human serum and urine concentrates. Proc. Soc. Exp. Biol. Med. 179: 296-299, 1985.
5. EMMANOUEL, D. S., GOLDWASSER, E. AND KATZ, A. I.: Metabolism of pure human erythropoietin in the rat. Am. J. Physiol. 274: F168-F176, 1984.
6. ESCHBACH, J. W., MLADENOVIC, J., GARCIA, J. F., WAHL, P. AND ADAMSON, J. W.: The anemia of chronic renal failure in sheep: The response to erythropoietin in vivo. J. Clin. Invest. 74: 434-441, 1984.
7. FLAHARTY, K. K., CARO, J., ERSLEV, A., WHALEN, J. J., MORRIS, E. M., BJORNSSON, T. D. AND VLASSES, P. H.: Phannacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin. Pharmacol. Ther. 47: 557-564, 1990.
8. FU, J.-S., LERTORA, J. L., BROOKINS, J., RICE, J. C. AND FISHER, J. W.: Pharmacokineties of erythropoietin in intact and anephric dogs. J. Lab. Clin. Med. 111: 669-676, 1988.
9. FUKUDA, M. N., SASAKI, H., LOPEZ, L. AND FUKUDA, M.: Survival of recombinant erythropoietin in the circulation: The role of carbohydrates. Blood 73: 84-89, 1989.
10. GAMMELTOFT, S.: Receptor-mediated endocytosis and degradation of polypeptide hormones, growth factors, and neuropeptides. In Degradation of Bioactive Substances: Physiology and Pathophysiology, ed. by J. H. Henriksen pp. 81-112, CRC Press, Boston, 1991.
11. GRIFFITH, B. P., SHAW, B. W., HARDESTY, R. L., IWATSUKI, S., BAHNSON, H. T. AND STARZL, T. E.: Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg. Gynecol. Obstet. 160: 271-273, 1985.
12. HILTON, D. J., WATOWICH, S. S., MURRAY, P. J. AND LODISH, H. F.: Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Proc. Natl. Acad. Sci. U.S.A. 92: 190-194, 1995.
13. JELKMANN, W.: Erythropoietin: Structure, control of production, and function. Physiol. Rev. 72: 449-489, 1992.
14. JENSEN, J. D., JENSEN, L. W., MADSEN, J. K AND POULSEN, L.: The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur. J. Haematol. 54: 111-116, 1995.
15. KENDALL, R. G., CHAPMAN, C., HARTLEY, A. E. AND NORFOLK, D. R.: Storage and preparation of samples for erythropoietin radioimmunoassay. Clin. Lab. Haematol. 13: 189-196, 1991.
16. KENNY, .A. J. AND HOOPER, N. M.: Peptidases involved in the metabolism of bioactive peptides. In Degradation of Bioactive Substances: Physiology and Pathophysiology, ed by J. H. Henriksen pp. 47-80, CRC Press, Boston, 1991.
17. KINOSHITA, H., OHISHI, N., TOKURA, S. AND OKAZAKI, A.: Pharmacokinetics and distribution of recombinant erythropoietin in rats with renal dysfunction. Drug Res. 42: 682-686, 1992a.
18. KINOSHITA, H., OHISHI, N., KATO, M., TOKUHA, S. AND OKAZAKI, A.: Pharmacokinetics and distribution of recombinant erythropoietin in rats. Drug Res. 42: 174-178, 1992b.
19. MACDOUGALL, I. C., ROBERTS, D. E., COLES, G. A. AND WILLIAMS, J. D.: Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 20: 99-113, 1991.
20. MLADENOVIC, J., ESCHBACH, J. W., KOUP, J. R., GARCIA, J. F. AND ADAMSON, J. W.: Erythropoietin kinetics in normal and uremic sheep. J. Lab. Clin. Med. 105: 659-663, 1985.
21. MUFSON, R. A. AND GESNER, T. G.: Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 69: 1485-1490, 1987.
22. NAETS, J. P. AND WITTEK, M.: Effect of erythroid hyperplasia on utilization of erythropoietin. Nature (Lond.) 206: 726-727, 1965.
23. NIELSEN, O. J.: Recombinant human erythropoietin: Experimental and clinical applications. Dan. Med. Bull. 38: 355-370, 1991.
24. NIELSEN, O. J., EGFJORD, M. AND HIRTH, P.: The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver 10: 343-349, 1990.
25. PIROSO, E., ERSLEV, A. J., FLAHARTY, K. K. AND CARO, J.: Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am. J. Hematol. 36: 105-110, 1991.
26. PORTER, D. L. AND GOLDBERG, M. A.: Regulation of erythropoietin production. Exp. Hematol. 21: 399-104, 1987.
27. SAWYER, S. T.: Receptors for erythropoietin: Distribution, structure, and role in receptor-mediated endocytosis in erythroid cells. In Blood Cell Biochemistry, ed. by J. R. Harris pp. 365-402, Plenum Press, New York, 1990.
28. SAWYER, S. T., KRANTZ, S. B. AND GOLDWASSER, E.: Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J. Biol. Chem. 262: 5554-5562, 1987.
29. SPIVAK, J. L. AND HOGANS, B. B.: The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73: 90-99, 1989.
30. STOHLMAN, F.: Observations on the physiology of erythropoietin and its role in the regulation of red cell production. Ann. N.Y. Acad. Sci. 77: 710-724, 1959.
31. VENG-PEDERSEN, P.: Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program, FUNFIT. J. Pharm. Biopharm. 5: 513-531, 1977.
32. VENG-PEDERSEN, P.: System approaches in pharmacokinetics. I. Basic concepts. J. Clin. Pharmacol. 28: 1-5, 1988.
33. VENG-PEDERSEN, P.: Mean time parameters in pharmacokinetics: Definition, computation and clinical implications. I. Clin. Pharmacokinet. 17: 345-366, 1989a.
34. VENG-PEDERSEN, P.: Mean time parameters in pharmacokinetics: Definition, computation and clinical implications. II. Clin. Pharmacokinet. 17: 424-440, 1989b.
35. VENG-PEDERSEN, P. AND GILLESPIE, W. R.: Theorems and implications of a model independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics. J. Pharmacokin. Biopharm. 17: 281-304, 1987.
36. VENG-PEDERSEN, P., WIDNESS, J. A., PEREIRA, L. M., PETERS, C., SCHMIDT, R. L. AND LOWE, L. S.: Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis: Application to the analysis of the non-linear elimination kinetics of erythropoietin in adult humans. J. Pharm. Sci. 84: 760-767, 1995.
37. WASLEY, L. C., TIMONY, G., MURTHA, P., SOUDEMIRE, J., DORNER, A. J., CARO, J., KRIEGER, M. AND KAUFMAN, R. J.: The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. Blood 77: 2624-2632, 1991.
38. WIDNESS, J. A., SCHMIDT, R. L., VENG-PEDERSEN, P., MODI, N. B. AND SAWYER, S. T.: A sensitive and specific erythropoietin immunoprecipitation assay: Application to pharmacokinetic studies. J. Lab. Clin. Med. 119: 285-294, 1992a.
39. WIDNESS, J. A., VENG-PEDERSEN, P., MODI, N. B., SCHMIDT, R. L. AND CHESTNUT, D. H.: Developmental differences in erythropoietin pharmacokinetics: Increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Ther. 261: 977-984, 1992b.
40. WIDNESS, J. A., VENG-PEDERSEN, P., PETERS, C., PERIERA, L., SCHMIDT, R. L. AND LOWE, L. S.: Erythropoietin pharmacokinetics in premature infants: Developmental, nonlinearity, and treatment effects. J. Appl. Physiol. 80: 140-148, 1996.
41. WINER, B. J.: Statistical Principles in Experimental Design, pp. 907, McGraw-Hill, New York, 1971.